当前位置: X-MOL 学术Expert Rev. Vaccines › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Moderate influenza vaccine effectiveness against A(H1N1)pdm09 virus, and low effectiveness against A(H3N2) subtype, 2018/19 season in Italy.
Expert Review of Vaccines ( IF 6.2 ) Pub Date : 2019-11-12 , DOI: 10.1080/14760584.2019.1688151
Stefania Bellino 1 , Antonino Bella 1 , Simona Puzelli 1 , Angela Di Martino 1 , Marzia Facchini 1 , Ornella Punzo 1 , Patrizio Pezzotti 1 , Maria Rita Castrucci 1 , The InfluNet Study Group
Affiliation  

Background: Influenza vaccines are updated every year to match the vaccine strains with currently circulating viruses; consequently influenza vaccine effectiveness (IVE) has to be assessed annually.Research design and methods: A test-negative case-control study was conducted within the context of the Italian sentinel influenza surveillance network to estimate IVE by age group, virus subtype, and vaccine brand in medically attended laboratory-confirmed influenza.Results: In Italy, the 2018/19 influenza season was characterized by the co-circulation of influenza A(H1N1)pdm09 and A(H3N2) viruses. The adjusted IVE estimate in preventing influenza was moderate (44.8%, 95% CI: 18.8 to 62.5) against A(H1N1)pdm09, whereas there was no evidence of effectiveness (1.8%, 95% CI: -37.8 to 30.1) in persons affected by A(H3N2). IVE against A(H1N1)pdm09 decreased with age ranging from 65.7% to 13.1% among children/adolescents and elderly, respectively; moreover results suggest that Vaxigrip Tetra® was more effective against A(H1N1)pdm09 compared to Fluarix Tetra® [62.5% (95% CI: 34.3 to 78.6) vs 24.5% (95% CI: -40.6 to 59.6)]. Low effectiveness (35.2%, 95% CI: -50.8 to 72.1) against A(H3N2) was detected only in the elderly immunized with Fluad®.Conclusions: Findings suggest that influenza vaccines were low to moderately effective, probably due to a mismatch between circulating and vaccine strains.

中文翻译:

在2018/19年度,意大利针对A(H1N1)pdm09病毒的流感疫苗效力中等,而针对A(H3N2)亚型的效力较低。

背景:流感疫苗每年都会更新,以使疫苗株与当前正在传播的病毒相匹配。研究设计和方法:在意大利前哨流感监测网络的背景下进行了测试阴性病例对照研究,以按年龄组,病毒亚型和疫苗估算IVE结果:在意大利,2018/19流感季节的特征是甲型流感(H1N1)pdm09和甲型流感(H3N2)共同传播。调整后的IVE估计值对A(H1N1)pdm09的流感预防为中度(44.8%,95%CI:18.8至62.5),而没有证据表明对人有效(1.8%,95%CI:-37.8至30.1)受A(H3N2)影响。在儿童/青少年和老年人中,针对A(H1N1)pdm09的IVE下降,年龄从65.7%降至13.1%;此外,结果表明,与FluarixTetra®相比,VaxigripTetra®对A(H1N1)pdm09更有效[62.5%(95%CI:34.3至78.6)对24.5%(95%CI:-40.6至59.6)]。仅在使用Fluad®免疫的老年人中检测到针对A(H3N2)的有效性较低(35.2%,95%CI:-50.8至72.1)。结论:研究结果表明,流感疫苗的效用低至中等,可能是由于两者之间的不匹配循环和疫苗株。
更新日期:2019-11-01
down
wechat
bug